Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + paclitaxel is a combination of two pharmaceutical agents used in oncology clinical trials for the treatment of advanced solid tumors. Axitinib is a potent and selective second-generation small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), blocking angiogenesis and tumor growth. Paclitaxel is a microtubule-stabilizing agent that binds to the β subunit of tubulin, preventing microtubule disassembly and thereby inhibiting cell division and inducing apoptosis in cancer cells. The combination has been studied for safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced solid tumors[1][2]. Axitinib is developed by Pfizer and marketed as Inlyta; paclitaxel is marketed as Taxol.
- Other names
- None
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on axitinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + paclitaxel.